Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Genelux Corporation (NASDAQ : GNLX) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Quote
| Last: | $2.945 |
|---|---|
| Change Percent: | -3.6% |
| Open: | $3.06 |
| Close: | $3.055 |
| High: | $3.07 |
| Low: | $2.92 |
| Volume: | 73,517 |
| Last Trade Date Time: | 06/05/2026 12:45:43 pm |
Stock Data
| Market Cap: | $92,073,203 |
|---|---|
| Float: | 34,698,662 |
| Insiders Ownership: | 0.72% |
| Institutions: | 28 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.genelux.com |
| Country: | US |
| City: | Westlake Village |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about Genelux Corporation (NASDAQ: GNLX).
